Dabigatran in secondary stroke prevention: clinical experience with 106 patients.

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet (2007) 10.10

Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 7.48

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. Europace (2012) 7.33

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48

Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet (1993) 5.77

Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain. Rev Esp Cardiol (Engl Ed) (2012) 3.29

Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol (2010) 3.26

Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke (2008) 3.14

Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol (2013) 3.13

Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke (2012) 3.02

Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med (2011) 2.45

Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation (2012) 2.18

Dabigatran and postmarketing reports of bleeding. N Engl J Med (2013) 2.15

Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation (2010) 1.68

Dabigatran etexilate: a new oral thrombin inhibitor. Circulation (2011) 1.66

Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2012) 1.62

Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost (2012) 1.51

International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J (2011) 1.20

Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. Lancet Neurol (2012) 1.18

Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. Am Heart J (2013) 1.02

The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation. Cerebrovasc Dis (2013) 0.93

New anticoagulant drugs among elderly patients is caution necessary?: Comment on "The use of dabigatran in elderly patients". Arch Intern Med (2011) 0.91

Guidelines for the preventive treatment of ischaemic stroke and TIA (II). Recommendations according to aetiological sub-type. Neurologia (2011) 0.88

Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval. Pharmacotherapy (2014) 0.87

Dabigatran in atrial fibrillation: balancing secondary stroke prevention against bleeding risk. Lancet Neurol (2010) 0.79

[Prevention of cardioembolic stroke]. Neurologia (2012) 0.77

[Controversy. Dabigatran in the preventive treatment of embolic stroke: arguments in favour of its utilisation as a first-choice drug]. Rev Neurol (2012) 0.77

[Advances in the prevention of cerebral ischaemia due to atrial fibrillation]. Neurologia (2010) 0.76